CancerAppy

Artificial Intelligence to optimize cancer drug development

CancerAppy

to transform the world of cancer research

Novel artificial intelligence platform for drug development and personalized medicine

Our Services

HEALTH CARE ONCOLOGY WORKFLOW

HEALTH CARE ONCOLOGY WORKFLOW
  • FDA Approved Drugs
  • Medical indications
  • Pharmacology toxicities
  • Drugs interactions
  • Ongoing clinical studies
  • European and American guidelines
  • Molecular Biomarkers for personalized medicine
  • Real World Data
  • Best workflow to reduce medical effort

 

PRECISION MEDICINE SOLUTIONS

PRECISION MEDICINE SOLUTIONS
  • Genomic Molecular Alterations
  • Evaluation of oncogenic molecular panels
  • Druggable vulnerabilities
  • Targered agents
  • Therapeutic opportunities
  • Drug combinations
  • Ongoing clinical studies
  • Identification of best treatment based on propietary algorithms

 

BIOMARKER AND DRUG DEVELOPER

BIOMARKER AND DRUG DEVELOPER
  • Genomic molecular alterations
  • Potential target inhibition
  • Druggable vulnerabilities
  • Current clinical development
  • Competitive landscape
  • Target population and indication
  • Evaluation of attrition rate
  • Pharma intelligent
  • Identification of best clinical development

 

What we do

This platform uses data from different sources including molecular alterations, scientific results, clinical trials, combinations of compounds, described efficacy, competitive landscape, in addition to side effects or potential interactions, to provide the user with all relevant data in a customized manner, without the necessity to obtain this information through complex consulting dossiers.

In addition, we are developing algorithms that can help to predict the success of a new pharmacological compound through the identification of unmet necessities, empty areas, potential side effects or combinations that would not reach the clinical setting, as well as crowded sectors or areas for business development.

Request an online test

We would be happy to show you our platform.